Literature DB >> 7142788

A radioimmunoassay for erythropoietin: serum levels in normal human subjects and patients with hemopoietic disorders.

A B Rege, J Brookins, J W Fisher.   

Abstract

An RIA for Ep has been developed that is highly sensitive and specific. A homogeneous Ep preparation was labeled with 125 I by the chloramine-T method to a specific activity of 90 to 136 micro Ci/microgram and immunoreactivity of 80%. Ep antiserum, which was produced to a human urinary Ep preparation (80 U/mg of protein), was adsorbed with normal human urinary and serum proteins without any loss in sensitivity of the RIA to increase the specificity of the assay. A good correlation was seen between the RIA and the exhypoxic polycythemic mouse assay (corr. coef. 0.967; slope 1.05 and "y" intercept 0.75). Ep titers in sera from 175 hematologically normal human subjects exhibited a normal frequency distribution and ranged between 5.8 and 36.6 mU/ml with a mean of 14.9 +/- 4.7 (S.D.) and median of 14.3 Serum Ep titers were markedly elevated in seven patients with aplastic anemia and one patient with pure red cell aplasia (1350 to 20,640 mU/ml) and were lower than normal in two patients with polycythemia vera (8.1 and 9.4 mU/ml). The serum Ep titers in a prenephrectomy patient with chronic glomerulonephritis (32.1 mU/ml) decreased to below normal levels (9.04 mU/ml) after nephrectomy. The cord serum erythropoietin titers in 10 IDM [90.82 +/- 134.1 (S.D.) mu/ml] returned to values within the normal range (13.86 +/- 5.55) on day 3 after birth, suggesting the utility of the RIA in elucidating the role of hypoxia and/or insulin in increased erythropoiesis in IDM. The serum Ep titers in patients with anemias and polycythemias were compared to those of normal human subjects and agreed well with pathophysiologic mechanisms of these hemopoietic disorders, confirming the validity of the RIA.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7142788

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  9 in total

1.  Lack of sex dependence of the serum level of immunoreactive erythropoietin in chronic anemia.

Authors:  W Jelkmann; G Wiedemann
Journal:  Klin Wochenschr       Date:  1989-12-04

2.  Renal mesangial cell cultures as a model for study of erythropoietin production.

Authors:  A Kurtz; W Jelkmann; F Sinowatz; C Bauer
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

3.  Erythropoietin in capillary hemangioblastoma. An immunohistochemical study.

Authors:  T Böhling; M Haltia; K Rosenlöf; F Fyhrquist
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

4.  Measurement of erythropoietin in anephric children. A report of the Southwest Pediatric Nephrology Study Group.

Authors:  B S Beckman; J W Brookins; M M Garcia; J W Fisher
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

5.  Role of endogenous prostaglandin E2 in erythropoietin production and dome formation by human renal carcinoma cells in culture.

Authors:  M Hagiwara; D B McNamara; I L Chen; J W Fisher
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

6.  Serum immunoreactive erythropoietin of children in health and disease.

Authors:  K U Eckardt; W Hartmann; U Vetter; F Pohlandt; R Burghardt; A Kurtz
Journal:  Eur J Pediatr       Date:  1990-04       Impact factor: 3.183

7.  Effect of different modes of dialysis on serum erythropoietin levels in pediatric patients. A report of the Southwest Pediatric Nephrology Study Group.

Authors:  B S Beckman; J W Brookins; R K Shadduck; K F Mangan; L J Deftos; J W Fisher
Journal:  Pediatr Nephrol       Date:  1988-10       Impact factor: 3.714

8.  Increased plasma viscosity as a reason for inappropriate erythropoietin formation.

Authors:  A Singh; K U Eckardt; A Zimmermann; K H Götz; M Hamann; P J Ratcliffe; A Kurtz; W H Reinhart
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

9.  The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

Authors:  T Salmonson; B G Danielson; B Wikström
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.